What does it mean to be HER2 Positive in Lung Cancer

Join us for an insightful episode of the Oncology Brothers podcast as we dive into the fast-evolving landscape of HER2-positive non-small cell lung cancer (NSCLC). In this first part of the two-part series, Drs. Rahul and Rohit Gosain were joined by Dr. Devika Das, a thoracic medical oncologist, and Dr. Fernando Lopez-Rios, a pathologist, to discuss the critical importance of testing and identifying HER2 alterations in lung cancer patients.

In this episode, we covered:
•⁠  ⁠The significance of HER2 alterations in NSCLC and how they differ from breast and gastric cancers.
•⁠  ⁠The complexities of biomarker testing, including NGS, IHC, and FISH amplification.
•⁠  ⁠Patient characteristics and phenotypes associated with HER2-positive disease.
•⁠  ⁠The current testing workflows in clinical practice and the role of liquid biopsies.
•⁠  ⁠Insights into the treatment landscape for HER2-positive NSCLC, including recent FDA approvals and ongoing clinical trials.

Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable information on the integration of precision medicine in lung cancer treatment.

YouTube: https://youtu.be/gMi-sflQyQo

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠  Website: https://oncbrothers.com/

Don't forget to subscribe for the next episode, where we will explore treatment options for HER2-positive non-small cell lung cancer in greater detail!